Opus Genetics (IRD) said that the FDA has granted Fast Track designation for Phentolamine Ophthalmic Solution 0.75% as a ...

FDA Fast Track Designation granted for Phentolamine Ophthalmic Solution 0.75% as treatment of significant chronic night ...

First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 ...

Opus Genetics (IRD) announced that the first pediatric patient was dosed in its ongoing Phase 1/2 clinical trial evaluating OPGx-LCA5, its ...

Opus Genetics, Inc., a pharmaceutical company specializing in preparations with a market capitalization of $35.67 million, has announced the date for its 2025 Annual Meeting of Stockholders.

(RTTNews) - Opus Genetics, Inc. (IRD), a clinical-stage ophthalmic biotechnology company, on Tuesday announced that the first pediatric patient has been dosed in its global Phase 1/2 clinical ...

Opus Genetics (IRD) announced completion of enrollment in the VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% ...

Early intervention in pediatric LCA5 patients is particularly important, as it offers the best chance to preserve or restore visual function before the disease progresses,” said George Magrath, M.D., ...

Early intervention in pediatric LCA5 patients is particularly important, as it offers the best chance to preserve or restore visual function before the disease progresses," said George Magrath, M.D., ...